NCT00676780|CompletedPhase 2ResultsDMC
Loading search results
Sponsor study identifier
interventional
33
1 country
1
Study Start
May 2004
Date type not reportedThis date has not been verified as actual or estimated.
Primary Completion
December 2008
Actual (reported)Study Completion
December 2008
Actual (reported)The purpose of the study is to see if a green tea extract can beneficially alter several markers of cancer risk and progression.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
December 2008
Actual (reported)Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
May 2004
Date type not reportedThis date has not been verified as actual or estimated.
May 9, 2008
Actual (reported)May 13, 2008
Actual (reported)December 2008
Actual (reported)December 2008
Actual (reported)August 8, 2012
Actual (reported)Change in Serum Prostate Specific Antigen (PSA) of Prostate Cancer
Change in serum prostate specific antigen (PSA) from baseline to post Polyphenol E treatment.
Baseline and 6 weeks
Change in Serum Vascular Endothelial Growth Factor (VEGF) and Prostate Cancer.
Change in serum vascular endothelial growth factor (VEGF) from baseline to post Polyphenol E treatment.
Baseline and 6 weeks.
Change in Serum Hepatocyte Growth Factor (HGF) and Prostate Cancer.
Change in serum hepatocyte growth factor (HGF) from baseline to post Polyphenol E treatment.
Baseline and 6 weeks
Single arm for a phase II study
4 capsules daily with a meal for the duration of the study
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
LSU Health Sciences Center
Shreveport, Louisiana, 71103, United States
McLarty J, Bigelow RL, Smith M, Elmajian D, Ankem M, Cardelli JA. Tea polyphenols decrease serum levels of prostate-specific antigen, hepatocyte growth factor, and vascular endothelial growth factor in prostate cancer patients and inhibit production of hepatocyte growth factor and vascular endothelial growth factor in vitro. Cancer Prev Res (Phila). 2009 Jul;2(7):673-82. doi: 10.1158/1940-6207.CAPR-08-0167. Epub 2009 Jun 19.
Patient compliance was an issue.
Jerry W McLarty, Ph.D.
LSUHSC Shreveport
33 participants (actual enrollment reported by the registry).
First Submitted
May 9, 2008
First Posted
May 13, 2008
Study Start
May 2004
Date type not reportedThis date has not been verified as actual or estimated.
Contact the study team to confirm eligibility.
Primary Completion
December 2008
Actual (reported)Study Completion
December 2008
Actual (reported)Last Updated
August 8, 2012
Results First Posted
August 8, 2012
Record last verified: 2012-06
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: